Cytotoxic etherphospholipid analogues

General Pharmacology

Volumn 31, Issue 4, 1998, Pages 511-517

  Berkovic, Dinko ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

Alkyllysophospholipid; Alkylphosphocholine; Edelfosine; Etherlysophospholipid; Hexadecylphosphocholine; Ilmofosine; Miltefosine

Indexed keywords

ALKYLLYSOPHOSPHOLIPID; EDELFOSINE; ETHER PHOSPHOLIPID; GLYCEROPHOSPHOLIPID; ILMOFOSINE; LYSOPHOSPHOLIPID; MILTEFOSINE;

CANCER CELL; CELL MATURATION; CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; HUMAN; IMMUNE RESPONSE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; ENZYME INHIBITORS; HUMANS; PHOSPHOLIPID ETHERS; PHOSPHORYLCHOLINE;

EID: 0032189615     PISSN: 03063623     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-3623(98)00081-0     Document Type: Review

References (105)

1. Andreesen R., Modolell M., Weltzien H.U., Eibl H., Common H.H., Löhr G.W., Munder P.G. Selective destruction of human leukemic cells by alkyl-lysophospholipids. Cancer Res. 38:1978;3894-3899.
2. Andreesen R., Modolell M., Munder P.G. Selective sensitivity of chronic myelogenous leukemia cell populations to alkyl-lysophospholipids. Blood. 54:1979;519-523.
3. Andreesen R., Osterholz J., Luckenbach G.A., Costabel U., Schulz A., Speth V., Munder P.G., Lohr G.W. Tumor cytotoxicity of human macrophages after incubation with synthetic analogues of 2-lysophosphatidylcholine. J. Natl. Cancer Inst. 72:1984;53-59.
4. Arnold B., Staber F.G., Miller J.F.A.P. Lysolecithins analogs as adjuvants in delayed-type hypersensitivity in mice. II. Studies on the mode of action. Eur. J. Immunol. 9:1979;367-370.
5. Bazill G.W., Dexter T.M. Role of endocytosis in the action of ether lipids on WEHI-3B, HL 60, and FDCP-mix cells. Cancer Res. 50:1990;7505-7512.
6. Becher R., Kloke O., Füger A., Bremer K., Drozd A., Kleeberg U.R., Fritze D., Rieche K., Sindermann H. Phase II trial of orally administered miltefosine in advanced colorectal cancer. Onkologie. 16:1993;11-15.
7. Berdel W.E., Bausert W.R., Weltzien H.U., Modolell M., Wickman K.H., Munder P.G. The influence of alkyl-lysophospholipids and lysolphospholipid-activated macrophages on the development of metastasis of 3 Lewis Lung carcinomas. Eur. J. Cancer. 16:1980;1199-1204.
8. Berdel W.E., Bausert W.R.E., Fink U., Rastetter J., Munder P.G. Anti-tumor action of alkyl-lysophospholipids. Anticancer Res. 1:1981;345-352.
9. Berdel W.E., Schlehe H., Fink U., Emmerich B., Maubach P.A., Emslander H.P., Daum S., Rastetter J. Early tumor and leukemia response to alkyl-lysophospholipids in a phase I study. Cancer. 50:1982;2011-2015.
10. Berdel W.E., Greiner E., Fink U., Stavrou D., Reichert A., Rastetter J., Hoffman D.R., Snyder F. Cytotoxicity of alkyl-lysophospholipids derivatives and low alkyl-cleavage enzyme activities in rat brain tumor cells. Cancer Res. 43:1983;541-545.
11. Berdel W.E., Becher R., Edler L., Bremer K., Essers U., Drozd A., Zafferani M., Klee M.A.G., Bachmann P., Korfel A., Westerhausen M. Daily oral miltefosine (hexadecylphosphocholine) in patients with advanced non-small-cell lung cancer. A phase II study. Onkologie. 15:1992;238-242.
12. 3 on methylnitrosoureainduced rat mammary carcinomas. Oncology. 41:1984;109-113.
13. 3 in chemically induced autochtonous rat tumors. J. Cancer Res. Clin. Oncol. 111:1986;47.
14. Bergren M.I., Gallegos A., Dressler L.A., Modest E.J., Powis G. Inhibition of the signalling enzyme phosphatidylinositol-3-kinase by antitumor ether lipid analogues. Cancer Res. 53:1993;4297-4302.
15. Berkovic D., Berkovic K., Fleer E.A.M., Eibl H., Unger C. Inhibition of calcium-dependent protein kinase C by hexadecylphosphocholine and 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine do not correlate with inhibition of proliferation of HL 60 and K 562 cell lines. Eur. J. Cancer. 30A:1994;509-515.
16. Berkovic D., Grunwald U., Menzel W., Unger C., Hiddemann W., Fleer E.A.M. Effects of hexadecylphosphocholine on membrane phospholipid metabolism in human tumour cells. Eur. J. Cancer. 31A:1995;2080-2085.
17. Berkovic D., Goeckenjan M., Unger C., Hiddemann W., Fleer E.A.M. Hexadecylphosphocholine inhibits phosphatidylinositol- and phosphatidylcholine-specific phospholipase C in human leukemic cells. J. Exp. Ther. Oncol. 1:1996;302-311. a.
18. Berkovic D., Haase D., Hiddemann W., Fleer E.A.M. Induction of resistance in the human leukemia cell line HL60 towards hexadecylphosphocholine and other ether phospholipid analogues. J. Exp. Ther. Oncol. 1:1996;368-376. b.
19. 2 in human leukemia cells by the etherphospholipid analogue hexadecylphosphocholine. Biochem. Pharmac. 53:1997;1725-1733. a.
20. Berkovic D., Hiddemann W., Kuduz J., Fleer E.A.M. Expression of two 50kDa proteins is associated with sensitivity towards etherlipid analogues in the human leukaemia cell line HL 60. Eur. J. Cancer. 33:1997;1875-1880. b.
21. Besson P., Gore J., Vincent E., Hoinard C., Bougnoux P. Inhibition of Na+/H+ exchanger activity by an alkyl-lysophospholipid analogue in a human breast cancer cell line. Biochem. Pharmac. 51:1996;1153-1158.
22. 3) on human umbilical vein or microvascular endothelium. Pathobiology. 63:1995;109-114.
23. Botzler C., Kolb H.J., Issels R.D., Multhoff G. Noncytotoxic alkyl-lysophospholipid treatment increases sensitivity of leukemic K562 cells to lysis by natural killer (NK) cells. Int. J. Cancer. 65:1996;633-638.
24. Burdzy K., Munder P.G., Fischer H., Westphal O. Steigerung der Phagozytose von Peritonealmakrophagen durch Lysolecithin. Z. Naturforsch. 19b:1964;1118-1120.
25. 3. Cancer Chemother. Pharmac. 34:1994;175-178.
26. Chabot M.C., Wykle R.L., Modest E.J., Daniel L.W. Correlation of ether lipid content of human cell lines and their susceptibility to 1-0-octadecyl-2-0-methyl-rac-glycero-3-phosphocholine. Cancer Res. 49:1989;4441-4445.
27. Cornell R., Vance D.E. Translocation of CTP:phosphocholine cytidylyltranferase from cytosol to membranes in HeLa cells. stimulation by fatty acid, fatty alcohol, mono- and diacylglycerol Biochim. Biophys. Acta. 919:1987;26-36.
28. Croft S.L., Neal R.A., Pendergast W., Chan J.H. The activity of alkyl phosphorylcholines and related derivatives against Leishmania Donovani. Biochem. Pharmac. 36:1987;2633-2636.
29. 3 inhibits nuclear factor-kappa B activation by 12-O-tetradecanoylphorbol-13-acetate but not by tumor necrosis factor alpha or interleukin 1 alpha. Cancer Res. 55:1995;4844-4849.
30. Diomede L., Bizzi A., Magistrelli A., Modest E.J., Salmona M., Noseda A. Role of cell cholesterol in modulating antineoplastic ether lipid uptake, membrane effects and cytotoxicity. Int. J. Cancer. 46:1990;341-346.
31. Diomede L., Colotta F., Piovani B., Re F., Modest E., Salmona M. Induction of apoptosis in human leukemic cells by the ether lipid 1-Octadecyl-2-methyl-rac-glycero-3-phosphocholine. A possible basis for its selective action. Int. J. Cancer. 53:1993;124-130.
32. Diomede L., Piovani B., Re F., Principe P., Colotta F., Modest E., Salmona M. The induction of apoptosis is a common feature of the cytotoxic action of ether-linked glycerophospholipids in human leukemic cells. Int. J. Cancer. 57:1994;645-649.
33. Dummer R., Röger J., Vogt T., Becker J., Hefner H., Sindermann H. and Burg G. (1992) Topical application of hexadecylphosphocholine in patients with cutaneous lymphomas. In Progress in Experimental Tumor Research. (Edited by Eibl H., Hilgard P. and Unger C.) Alkylphosphocholines: New drugs in cancer therapy, pp. 160-170. Vol. 34. Karger-Verlag, Basel.
34. Engelmann J., Henke J., Wilker W., Kutscher B., Nossner G., Engel J., Leibfritz D. Early stage monitoring of miltefosine induced apoptosis in KB cells by multinuclear NMR spectroscopy. Anticancer Res. 16(3B):1996;1429-1439.
35. Eue I., Zeisig R., Arndt D. Alkylphosphocholine-induced production of nitric oxide and tumor necrosis factor α by U937 cells. J. Cancer Res. Clin. Oncol. 121:1995;350-356.
36. Fleer E.A.M., Unger C., Kim D.J., Eibl H. Metabolism of ether phospholipids and analogues in neoplastic cells. Lipids. 22:1987;856-861.
37. Fleer E.A.M., Berkovic D., Eibl H., Unger C. Investigations on the cellular uptake of hexadecylphosphocholine. Lipids. 28:1993;731-736.
38. Fleer E.A.M., Berkovic D., Grunwald U., Hiddemann W. Induction of resistance to hexadecylphosphocholine in the highly sensitive human epidermoid tumour cell line KB. Eur. J. Cancer. 13:1996;506-511.
39. Geilen C.C., Wieder T., Reutter W. Hexadecylphosphocholine inhibits translation of CTP. cholinephosphate-cytidylyltransferase in Madin-Darby canine kidney cells J. Biol. Chem. 267:1992;6719-6724.
40. Glasser L., Somberg L.B., Vogler W.R. Purging murine leukemic marrow with alkyl-lysophospholipids. Blood. 64:1984;1288-1295.
41. Haase R., Wieder T., Geilen C.C., Reutter W. The phospholipid analogue hexadecylphosphocholine inhibits phosphatidylcholine biosynthesis in Madin-Darby canine kidney cells. FEBS Letters. 288:1991;129-132.
42. 3 acts as an activator of protein kinase C in HL 60 cells. FEBS Letters. 290:1991;231-234.
43. Heesbeen E.C., Verdonck L.F., Staal G.E.J., Rijksen G. Protein kinase C is not involved in the cytotoxic action of 1-O-octadecyl-2-O-methyl-sn-glycero-3-phosphocholine in HL 60 and K 562 cells. Biochem. Pharmac. 47:1994;1481-1488.
44. Herrmann D.B.J. Changes in cellular lipid synthesis of normal and neoplastic cells during cytolysis induced by alkyl lysophospholipid analogues. J. Natl. Cancer Inst. 75:1985;219-222.
45. Hilgard P., Stekar J., Voegeli R., Engel J., Schumacher W., Eibl H., Unger C., Berger M.R. Characterization of the antitumor activity of hexadecylphosphocholine (D 18506). Eur. J. Clin. Oncol. 24:1988;1457-1467.
46. Hilgard P., Kampkern E., Nolan L., Pohl J., Reissman T. Investigation into the immunological effects of miltefosine, a new anticancer agent under development. J. Cancer Res. Clin. Oncol. 117:1991;403-408.
47. Hochhuth C., Berkovic D., Eibl H., Unger C., Doenecke D. Effects of neoplastic phospholipids on parameters of cell differentiation in U 937 cells. J. Cancer Res. Clin. Oncol. 116:1990;459-466.
48. Hochhuth C., Vehmeyer K., Eibl H., Unger C. Hexadecylphosphocholine induces interferon-gamma secretion and expression of GM-CSF mRNA in human mononuclear cells. Cell Immunol. 141:1992;161-168.
49. Hoffman D.R., Hoffman L.H., Snyder F. Cytotoxicity and metabolism of alkyl phospholipid analogues in neoplastic cells. Cancer Res. 46:1986;5803-5809.
50. Hoffman D.R., Thomas V.L., Snyder F. Inhibition of cellular transport systems by alkyl phospholipid analogs in HL60 human leukemic cells. Biochim. Biophys. Acta. 1127:1992;74-80.
51. Hofmann J., O'Connor P.M., Jackman J., Schubert C., Überall F., Kohn K.W., Grunicke H. The protein kinase C inhibitor ilmofosine (BM41.440) arrests cells in G2 phase and supresses CDC2 kinase activation through a mechanism different from that of DNA damaging agents. Biochem. Biophys. Res. Commun. 199:1994;937-943.
52. Hwang S.B., Lee C.S.C., Cheah M.J., Shen T.Y. Specific receptor sites for 1-0-alkyl-2-0-acetyl-sn-glycero-3-phosphocholine (platelet activating factor) on rabbit platelet and guinea pig smooth muscle membranes. Biochemistry. 22:1983;4756-4763.
53. Infante J.P. Rate-limiting steps in the cytidine pathway for the synthesis of phosphatidylcholine and phosphatidylethanolamine. Biochem. J. 167:1977;847-849.
54. Kaufman-Kolle P., Fleer E.A.M., Kötting J., Behnert C., Unger C., Eibl H. Liposomal hexadecylphosphocholine. Characterization and effects on adherent tumor cells J. Liposome Res. 4:1994;1115-1134.
55. Kosano H., Takatani O. Reduction of epidermal growth factor binding in human breast cancer cell lines by an alkyl-lysophospholipid. Cancer Res. 49:1988;2868-2870.
56. Kosano H., Takatani O. Inhibition by an alkyl-lysophospholipid of the uptake of epidermal growth (EGF) in human breast cancer cell lines in relation to EGF internalization. Cancer Res. 49:1989;2868-2870.
57. Kuhlencord A., Maniera T., Eibl H.J., Unger C. Hexadecylphosphocholine. oral treatment of visceral Leishmaniasis in mice Antimicrob. Agents Chemother. 36:1992;1630-1634.
58. Lu X., Arthur G. Perturbations of cellular acylation processes by the synthetic alkyl-lysophospholipid 1-O-octadecyl-2-O-methyl-glycero-3-phosphocholine do not correlate with inhibition of proliferation of MCF 7 and T 84 cell lines. Cancer Res. 52:1992;2806-2812. a.
59. 3 does not correlate with the relative effects of the alkyllysophospholipid on the incorporation of fatty acids into cellular phospholipids. Cancer Res. 52:1992;2813-2817. b.
60. ++ transport. J. Biol. Chem. 243:1968;61-71.
61. Maurer H. R. and Hilgard P. (1992) Induction of tumor cell differentiation by alkylphosphocholines: a new approach for invitro screening. In Progress in Experimental Tumor Research; Alkylphosphocholines (Edited by Eibl H., Hilgard P. and Unger C.), New Drugs in Cancer Therapy, Volume 34; pp. 90-97. Karger-Verlag, Basel.
62. McNamara M.J.C., Schmitt J.D., Wykle R.L., Daniel L.W. 1-0-hexadecyl-2-acetyl-sn-glycerol stimulates differentiation of HL 60 human promyelocytic leukemia cells to macrophage-like cells. Biochem. Biophys. Res. Commun. 122:1984;824-830.
63. Modollel M., Andreesen R., Pahlke W., Brugger U., Munder P.G. Disturbance of phospholipid metabolism during selective destruction of tumor cells induced by alkyllysophospholipids. Cancer Res. 39:1985;4681-4686.
64. Munder P.G., Modolell M., Raetz W., Luckenbach G.A. Primary antibody formation in vitro by mouse cells in a complete homologous system. Eur. J. Immunol. 3:1973;454-457.
65. 3 and BM 41.440. Biochem. Biophys. Res. Commun. 157:1988;1000-1006.
66. Okamoto S., Olson A.C., Vogler W.R., Winton E.F. Purging leukemic cells from simulated human remission marrow with alkyl-lysophospholipid. Blood. 69:1987;1381-1388.
67. Okamoto S., Olson A.C., Berdel W.E., Vogler W.R. Purging of acute myeloid leukemia cells by ether lipids and hyperthermia. Blood. 72:1988;1772-1783.
68. Pawelczyk T., Lowenstein J.M. Inhibition of phospholipase C by hexadecylphosphopholine and lysophospholipids with antitumor activity. Biochem. Pharmac. 45:1993;493-497.
69. Planting A., Verweji J., Hoff A., Drees A., Seynalve C., Stoter G. Phase II study of daily oral hexadecylphosphocholine in advanced colorectal cancer. Ann. Oncol. 1(Suppl.):1990;46.
70. Posse-de-Chaves E., Vance D.E., Campenot R.B., Vance J.E. Alkylphosphocholines inhibit choline uptake and phosphatidylcholine biosynthesis in rat sympathetic neurons and impair axonal extension. Biochem. J. 312:1995;411-417.
71. Powis G., Seewald M.J., Gratas C., Milder D.C., Riebow J., Modest E.J. Selective inhibition of phosphatidylinositol phospholipase C by cytotoxic ether lipid analogues. Cancer Res. 52:1992;2835-2840.
72. Principe P., Sidoti C., Braquet P. Tumor cell killing following antineoplastic ether phospholipid treatment. Cancer Res. 52:1992;2509-2515.
73. Pronk L.C., Planting A.S.T., Oosterom R., Drogendijk T.E., Stoter G., Verweji J. Increases in leucocyte and platelet counts induced by the alkyl phospholipid hexadecylphosphocholine. Eur. J. Cancer. 30A:1994;1019-1022.
74. Salari H., Dryden P., Davenport R., Howard S., Jones K., Bittman R. Inhibition of protein kinase C by ether-linked lipids is not correlated with their antineoplastic activity on WEHI-3B and R6X-B15 cells. Biochim. Biophys. Acta. 1134:1992;81-88.
75. Schallier D.C., Bruyneel E.A., Storme G.A., Hilgard P., Mareel M.M. Antiinvasive activity of hexadecylphosphocholine in vitro. Anticancer Res. 11:1991;1285-1292. a.
76. 3. Clin. Exp. Metastasis. 9:1991;579-591. b.
77. ++ signalling by antitumor ether lipid analogues. Cancer Res. 50:1990;4458-4463.
78. Shames R., Ruis N.M., Valone F.H. Tumor necrosis factor release by murine macrophages stimulated by the cytotoxic ether lipid 1-O-hexadecyl-2-O-methyl-sn-glycero-3-phosphorylcholine (ET-18-O-OCH3). Int. J. Immunopharmac. 16:1994;335-343.
79. Shier W.T., Baldwin J.H., Nilsen-Hamilton M., Hamilton R.T., Thanassi N.M. Regulation of guanylate and adenylate cyclase activities by lysolecithin. Proc. Natl. Acad. Sci. USA. 73:1976;1586-1590.
80. Shoji M., Fukuhara T., Winton E.F., Berdel W.E., Vogler W.R. Different mechanisms of inhibition by alkyl-lysophospholipid and phorbol ester of granulocyte-macrophage colony stimulating factor binding to human leukemic cell lines. Exp. Hematol. 22:1994;13-18.
81. Slaton J.W., Hampton J.A., Selman S.H. Exposure to alkyllysophospholipids inhibits in vitro invasion of transitional cell carcinoma. J. Urology. 152:1994;1594-1598.
82. Soodsma J.F., Piantadosi C., Snyder F. The biocleavage of alkylglycerol ethers in Morris Hepatomas and other transplantable neoplasms. Cancer Res. 30:1970;309-311.
83. Tarnowsky G.S., Mountain I.M., Stock C.C., Munder P.G., Weltzien H.U., Westphal O. Effect of lysolecithin and analogs on mouse ascites tumors. Cancer Res. 38:1978;339-344.
84. Tidwell T., Guzman G., Vogler W.R. The effect of alkyl-lysophopholipids on leukemic cell lines. I. Differential action on two human leukemic cell lines HL60 and K562. Blood. 54:1979;519-523.
85. Überall F., Oberhuber H., Maly K., Zaknun J., Demuth L., Grunicke H.H. Hexadecylphosphocholine inhibits inositol phosphate formation and protein kinase C activity. Cancer Res. 51:1991;807-812.
86. Unger C., Eibl H., von Heyden H.W., Nagel G.A. A new assay for the o-alkyl-cleavage enzyme with akyl-lysophospholipids as substrates. Cancer Res. 45:1985;616-618.
87. Unger C. (1989) Alkylphosphocholine und Analoga. Entwicklung einer neuen Substanzgruppe mit antineoplastischer Wirkung; Thieme, Stuttgart.
88. Unger C., Eibl H., Breiser A., von Heyden H.W., Engel J., Hilgard P., Sindermann H., Peukert M., Nagel G.A. Hexadecylphosphocholine (D18506) in the topical treatment of skin metastases. A phase I trial Onkologie. 11:1988;295-296.
89. Unger C., Peukert M., Sindermann H., Hilgard P., Nagel G.A., Eibl H. Hexadecylphosphocholine in the topical treatment of skin metastasis in breast cancer patients. Cancer Treatment Rev. 17:1990;243-246. a.
90. Unger C., Eibl H., von Heyden H.W., Peukert M., Sindermann H., Nagel G.A. Phase I study with daily hexadecylphosphocholine in patients with malignant disease. Cancer Res. Clin. Oncol. 116:1990;993. b.
91. Vallari D.S., Smith Z.L., Snyder F. HL 60 cells become resistant towards antitumor ether-linked phospholipids following differentiation into a granulocytic form. Biochem. Biophys. Res. Commun. 156:1988;1-8.
92. Vehmeyer K., Kim D.J., Nagel G.A., Eibl H., Unger C. Effect of ether lipids on mouse granulocyte-macrophage progenitor cells. Cancer Chemother. Pharmac. 24:1989;58-60.
93. Vehmeyer K., Scheurich P., Eibl H., Unger C. Hexadecylphosphocholine-mediated enhancement of T-cell responses to interleukin 2. Cell Immunol. 137:1991;232-238.
94. Verweji J., Planting A., van den Berg M., Stoter G. A dose finding study of miltefosine (hexadecylphosphocholine) in patients with metastatic solid tumors. J. Cancer Res. Clin. Oncol. 118:1992;606-608.
95. Voelker D.R., Kennedy E.P. Phospholipid exchange protein-dependent synthesis of sphingomyelin. Meth. Enzymol. 98:1983;596-598.
96. Vogler W.R., Whigham E., Bennett W.D., Olson A.C. Effect of alkyl-lysophospholipids on phosphatidylcholine biosynthesis in leukemic cell lines. Exp. Hematol. 13:1985;629-633.
97. Vogler W.R., Berdel W.E., Olson A.C., Winton E.F., Heffner L.T., Gordon D.S. Autologuous bone marrow transplantation in acute leukemia with marrow purged with alkyl-lysophospholipid. Blood. 80:1992;1423-1429.
98. Wagner B.A., Buettner G.R., Burns C.P. Membrane peroxidative damage enhancement by the ether lipid class of antineoplastic agents. Cancer Res. 52:1992;6045-6051.
99. Wagner B.A., Buettner G.R., Burns C.P. Increased generation of lipid-derived and ascorbate free radicals by L1210 cells exposed to the etherlipid edelfosine. Cancer Res. 53:1993;711-713.
100. Wieder T., Geilen C.C., Reutter W. Antagonism of phorbol ester-stimulated phosphatidylcholine biosynthesis by the phospholipid analogue hexadecylphosphocholine. Biochem. J. 291:1993;561-567.
101. Wieder T., Zhang Z., Geilen C.C., Orfanos C.E., Giuliano A.E., Cabot M.C. The antitumor phospholipid analog, hexadecylphosphocholine, activates cellular phospholipase D. Cancer Lett. 100:1996;71-79.
102. Winkelmann M., Ebeling K., Strohmeyer G., Hottenrott G., Mechl Z., Berges W., Scholten T., Westerhausen M., Schlimok G., Sterz R. Treatment results of the thioether lipid ilmofosine in patients with malignant diesease. Cancer Res. Clin. Oncol. 118:1992;405-407.
103. Zheng B., Oishi K., Shoji M., Eibl H., Berdel W.E., Hajdu J., Vogler W.R., Kuo J.F. Inhibition of protein kinase C (sodium plus potassium)-activated adenosine triphosphatase, and sodium pump by synthetic phospholipid analogues. Cancer Res. 50:1990;3025-3031.
104. Zhou X., Arthur G. Effect of 1-O-octadecyl-2-O-methyl-glycerophosphocholine on phospatidylcholine and phosphatidylethanolamine synthesis in MCF-7 and A549 cells and its relationship to inhibition of cell proliferation. Eur. J. Biochem. 232:1995;881-888.
105. Zhou X., Lu X., Richard C., Xiong W., Litchfield D.W., Bittman R., Arthur G. 1-O-octadecyl-2-O-methyl-glycerophosphocholine inhibits the transduction of growth signals via the MAPK cascade in cultured MCF-7 cells. J. Clin. Invest. 98:1996;937-944.